Institution Directory

Clinical trials at UT Southwestern Medical Center

Sites in Dallas, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1259

Shown on this page

Current sort

Live official records

Conditions: Congenital Diaphragmatic Hernia
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2027
U.S. locations: 13
States / cities: Chicago, Illinois • Ann Arbor, Michigan • St Louis, Missouri + 9 more

Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions: Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel; Drug · Procedure
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 78
States / cities: Irvine, California • Los Angeles, California • Orange, California + 64 more

Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2034
U.S. locations: 184
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more

Conditions: Inguinal Hernia, Anesthesia, Local
Interventions: Open Inguinal Hernia Repair - Local Anesthesia, Inguinal Hernia Repair - General Anesthesia; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 60 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Dallas, Texas • Houston, Texas • Madison, Wisconsin

Conditions: Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Interventions: Previously treated CAR-T patients; Genetic
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 0 Years to 100 Years
Enrollment: 1,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2039
U.S. locations: 42
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 21 more

Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Biospecimen Collection, Carboplatin, Cabazitaxel, Abiraterone Acetate, Enzalutamide, Lutetium Lu 177 Vipivotide Tetraxetan; Other · Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 108
States / cities: Birmingham, Alabama • Tucson, Arizona • Chico, California + 91 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 1023
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more

Conditions: Muscular Atrophy, Spinal
Interventions: Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Months to 24 Months
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 11
States / cities: Little Rock, Arkansas • Aurora, Colorado • Gainesville, Florida + 8 more

Conditions: Grade 2 Meningioma, Intracranial Meningioma
Interventions: Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment; Procedure · Other · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 198
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more

Conditions: Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin
Interventions: Apitegromab, Nusinersen, Risdiplam; Drug
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: Up to 2 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 9 more

Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Androgen Therapy, Apalutamide, Docetaxel, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, PSMA PET Scan, Biospecimen Collection, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2039
U.S. locations: 213
States / cities: Tucson, Arizona • Dublin, California • Fremont, California + 172 more

Conditions: Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 673
States / cities: Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more

About this UT Southwestern Medical Center institution page

What this page lists: ClinicalTrials.gov records that list UT Southwestern Medical Center in Dallas, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UT Southwestern Medical Center

Filter and sort this campus

Live official records

Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

A Pilot Study of Local Anesthesia for Inguinal Hernia Surgery in Older Adults

CAR-T Long Term Follow Up (LTFU) Study

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

About this UT Southwestern Medical Center institution page